Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. (0A8E.L) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Xeris Biopharma Holdings, Inc. (0A8E.L), featuring income statements, balance sheets, and cash flow data.
Xeris Biopharma Holdings, Inc. (0A8E.L) Income Statement & Financial Overview
Analyze Xeris Biopharma Holdings, Inc.’s 0A8E.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q1 2025 |
|---|---|---|---|
| Revenue | $48.06M | $54.27M | $54.27M |
| Cost of Revenue | $10.50M | $13.59M | $13.59M |
| Gross Profit | $37.56M | $40.67M | $40.67M |
| Gross Profit Ratio | $0.78 | $0.75 | $0.75 |
| R&D Expenses | $5.76M | $5.89M | $5.89M |
| SG&A Expenses | $39.99M | $44.97M | $44.97M |
| Operating Expenses | $45.75M | $53.57M | $53.57M |
| Total Costs & Expenses | $56.25M | $67.16M | $67.16M |
| Interest Income | $1.29M | $1.20M | $1.20M |
| Interest Expense | $7.96M | $7.79M | $7.79M |
| Depreciation & Amortization | $3.15M | $3.12M | $3.12M |
| EBITDA | -$3.14M | -$8.15M | -$8.15M |
| EBITDA Ratio | -$0.10 | -$0.15 | -$0.15 |
| Operating Income | -$8.19M | -$12.89M | -$12.89M |
| Operating Income Ratio | -$0.17 | -$0.24 | -$0.24 |
| Other Income/Expenses (Net) | -$6.07M | -$6.17M | -$6.17M |
| Income Before Tax | -$14.26M | -$19.06M | -$19.06M |
| Income Before Tax Ratio | -$0.30 | -$0.35 | -$0.35 |
| Income Tax Expense | $749000.00 | -$3.32M | -$3.32M |
| Net Income | -$15.005M | -$15.74M | -$15.74M |
| Net Income Ratio | -$0.31 | -$0.29 | -$0.29 |
| EPS | -$0.10 | -$0.11 | -$0.11 |
| Diluted EPS | -$0.10 | -$0.11 | -$0.11 |
| Weighted Avg Shares Outstanding | $148.35M | $148.99M | $148.99M |
| Weighted Avg Shares Outstanding (Diluted) | $148.35M | $148.99M | $148.99M |
Over the last four quarters, Xeris Biopharma Holdings, Inc.'s revenue moved from $54.27M in Q3 2024 to $54.27M in Q1 2025. Operating income in Q1 2025 was -$12.89M, with a strong operating margin of -24%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Xeris Biopharma Holdings, Inc. remained robust at -$8.15M, reflecting operational efficiency. Net income dropped to -$15.74M, with an EPS of -$0.11. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan